Exclusion Codes

• X1: Not published in English
• X2: Not original research
• X3: Ineligible population
• X4: Ineligible intervention
• X5: Ineligible comparator
• X6: Ineligible outcome
• X7: Ineligible setting
• X8: Ineligible study design
• X9: Treatment duration less than 12 weeks
• X10: Systematic review with search that ended prior to 2007

1.

Preventing Alcohol Withdrawal With Oral Baclofen. Exclusion Code: X7.

2.

Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: Rationale and methods. Alcohol. 2003;27(7):1107–22. Exclusion Code: X6. [PubMed: 12878917]

3.

The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence. 2013. Exclusion Code: X9.

4.

Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence. 2014. Exclusion Code: X7.

5.

Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care. 2018. Exclusion Code: X5.

6.

Harm Reduction With Pharmacotherapy (HaRP). 2018. Exclusion Code: X8.

7.

Abtahi MA, Abtahi SH, Fazel F, et al. Topiramate and the vision: A systematic review. Clin Opthalmol. 2012;6(1):117–31. Exclusion Code: X3. [PMC free article: PMC3261698] [PubMed: 22275816]

8.

Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002 Sep-Oct;37(5):504–8. Exclusion Code: X9. [PubMed: 12217947]

9.

Addolorato G, Leggio L, Ferrulli A, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011 May-Jun;46(3):312–7. Exclusion Code: X8. [PubMed: 21414953]

10.

Adler L, Wilens T, Zhang S, et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict. 2009 Sep-Oct;18(5):393–401. Exclusion Code: X8. [PubMed: 19874159]

11.

Agosti V, Nunes EV, O'shea D. Do manualized psychosocial interventions help reduce relapse among alcohol-dependent adults treated with naltrexone or placebo? A meta-analysis. Am J Addict. 2012;21(6):501–7. Exclusion Code: X5. [PubMed: 23082827]

12.

Aguiar P, Neto D, Lambaz R, et al. Prognostic factors during outpatient treatment for alcohol dependence: Cohort study with 6 months of treatment follow-up. Alcohol Alcohol. 2012;47(6):702–10. Exclusion Code: X5. [PubMed: 22986010]

13.

Ait-Daoud N, Johnson BA, Javors M, et al. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker. Alcohol Clin Exp Res. 2001 Jun;25(6):847–9. Exclusion Code: X4. [PubMed: 11410720]

14.

Ait-Daoud N, Johnson BA, Prihoda TJ, et al. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology (Berl). 2001 Feb;154(1):23–7. Exclusion Code: X4. [PubMed: 11292002]

15.

Aliyev NN. Trial of interferon in chronic alcoholism. Psychiatry Res. 1994;54(3):307–8. Exclusion Code: X5. [PubMed: 7792335]

16.

Allen JP, Sillamaukee P, Anton R. Contribution of carbohydrate deficient transferrin to gamma glutamyl transpeptidase in evaluating progress of patients in treatment for alcoholism. Alcohol Clin Exp Res. 1999 Jan;23(1):115–20. Exclusion Code: X4. [PubMed: 10029211]

17.

Altamura AC, Mauri MC, Girardi T, et al. Alcoholism and depression: a placebo controlled study with viloxazine. Int J Clin Pharmacol Res. 1990;10(5):293–8. Exclusion Code: X6. [PubMed: 2079386]

18.

Altintoprak AE, Zorlu N, Coskunol H, et al. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. Hum Psychopharmacol. 2008 Jun;23(4):313–9. Exclusion Code: X5. [PubMed: 18327889]

19.

Anderson N, Oliver MN. Oral topiramate effective for alcoholism. J Fam Pract. 2003;52(9):682–7. Exclusion Code: X2. [PubMed: 12967537]

20.

Angelone SM, Bellini L, Di Bella D, et al. Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics. Alcohol Alcohol. 1998 Mar-Apr;33(2):151–6. Exclusion Code: X8. [PubMed: 9566477]

21.

Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008 Aug 14;359(7):715–21. Exclusion Code: X2. [PMC free article: PMC2565602] [PubMed: 18703474]

22.

Anton RF, Moak DH, Latham PK. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996 Mar;53(3):225–31. Exclusion Code: X6. [PubMed: 8611059]

23.

Anton RF, Myrick H, Baros AM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009 Aug;29(4):334–42. Exclusion Code: X4. [PubMed: 19593171]

24.

Armeli S, Feinn R, Tennen H, et al. The effects of naltrexone on alcohol consumption and affect reactivity to daily interpersonal events among heavy drinkers. Exp Clin Psychopharmacol. 2006 May;14(2):199–208. Exclusion Code: X6. [PubMed: 16756424]

25.

Auriacombe M, Robinson M, Grabot D, et al. Naltrexone is ineffective to prevent relapse to alcohol in a realistic outpatient setting. A double blind one-year controlled study. College of Problems of Drug Dependence; San Juan, Puerto Rico: 2000. [abstract] Exclusion Code: X8.

26.

Back SE, Brady KT, Sonne SC, et al. Symptom improvement in co-occurring PTSD and alcohol dependence. J Nerv Ment Dis. 2006 Sep;194(9):690–6. Exclusion Code: X6. [PubMed: 16971821]

27.

Balldin J, Berggren U, Engel J, et al. Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res. 1994 Oct;18(5):1133–6. Exclusion Code: X3. [PubMed: 7847595]

28.

Baltieri DA, Correa Filho JM. Role of two clusters of male alcoholics in treatment retention. Eur Addict Res. 2012;18(4):201–11. Exclusion Code: X6. [PubMed: 22507891]

29.

Baltieri DA, de Andrade AG. Efficacy of acamprosate in the treatment of alcohol-dependent outpatients. Rev Bras Psiquiatr. 2003 Sep;25(3):156–9. Exclusion Code: X6. [PubMed: 12975689]

30.

Barber TJ, Marett B, Waldron S, et al. Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice? AIDS. 2007 Aug 20;21(13):1823–4. Exclusion Code: X8. [PubMed: 17690585]

31.

Baros AM, Latham PK, Anton RF. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008 May;32(5):771–6. Exclusion Code: X8. [PMC free article: PMC2553698] [PubMed: 18336635]

32.

Baros AM, Latham PK, Moak DH, et al. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007 Apr;31(4):596–603. Exclusion Code: X6. [PubMed: 17374038]

33.

Barrias JA, Chabac S, Ferreira L, et al. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clinica. 1997;18:149–60. Exclusion Code: X1.

34.

Basu D, Jhirwal OP, Mattoo SK. Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India. Am J Addict. 2005 Jul-Sep;14(4):381–95. Exclusion Code: X8. [PubMed: 16188718]

35.

Beresford TP, Arciniegas D, Clapp L, et al. Reduction of affective lability and alcohol use following traumatic brain injury: a clinical pilot study of anti-convulsant medications. Brain Inj. 2005 Apr;19(4):309–13. Exclusion Code: X6. [PubMed: 15832875]

36.

Berglund KJ, Balldin J, Berggren U, et al. Childhood maltreatment affects the serotonergic system in male alcohol-dependent individuals. Alcohol. 2013;37(5):757–62. 2013-15234-008. First Author & Affiliation: Berglund, Kristina J. Exclusion Code: X8. [PubMed: 23384117]

37.

Bergstrom B, Ohlin H, Lindblom PE, et al. Is disulfiram implantation effective? Lancet. 1982 Jan 2;1(8262):49–50. Exclusion Code: X5. [PubMed: 6119442]

38.

Blomqvist O, Hernandez-Avila CA, Burleson JA, et al. Self-Efficacy as a Predictor of Relapse during Treatment for Alcohol Dependence. Addict Disord Their Treat. 2003;2(4):135–45. Exclusion Code: X8.

39.

Bonnet U, Specka M, Leweke FM, et al. Gabapentin's acute effect on mood profile -- a controlled study on patients with alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):434–8. Exclusion Code: X3. [PubMed: 17178181]

40.

Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry. 1995 Nov;56(11):502–5. Exclusion Code: X5. [PubMed: 7592501]

41.

Brahen LS, Capone T, Heller RC, et al. Controlled clinical study of naltrexone side effects comparing first-day doses and maintenance regimens. Am J Drug Alcohol Abuse. 1978;5(2):235–45. CN-00019998. Exclusion Code: X3. [PubMed: 747177]

42.

Brahen LS, Henderson RK, Capone T, et al. Naltrexone treatment in a jail work-release program. J Clin Psychiatry. 1984;45(9, Sect 2):49–52. Exclusion Code: X3. [PubMed: 6469937]

43.

Brower KJ, Myra Kim H, Strobbe S, et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008 Aug;32(8):1429–38. Exclusion Code: X9. [PMC free article: PMC2927959] [PubMed: 18540923]

44.

Brunette MF, O'Keefe C, Zimmet S, et al. Clozapine, olanzapine, or typical antipsychotics for alcohol use disorder in patients with schizophrenia. J Dual Diagn. 2008;4(4):344–54. Exclusion Code: X8.

45.

Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology. 1989;22 Suppl 1:49–59. Exclusion Code: X9. [PubMed: 2657838]

46.

Bujarski S, O'Malley SS, Lunny K, et al. The effects of drinking goal on treatment outcome for alcoholism. J Consult Clin Psychol. 2013;81(1):13–22. Exclusion Code: X6. [PMC free article: PMC4166539] [PubMed: 23231573]

47.

Buri C, Moggi F, Giovanoli A, et al. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland. Alcohol Alcohol. 2007 Jul-Aug;42(4):333–9. Exclusion Code: X8. [PubMed: 17517820]

48.

Burman WJ, Terra M, Breese P, et al. Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis. Int J Tuberc Lung Dis. 2002;6(9):839–42. Exclusion Code: X8. [PubMed: 12234141]

49.

Capone C, Kahler CW, Swift RM, et al. Does family history of alcoholism moderate naltrexone's effects on alcohol use? J Stud Alcohol Drugs. 2011 Jan;72(1):135–40. Exclusion Code: X5. [PubMed: 21138720]

50.

Caputo F, Addolorato G, Lorenzini F, et al. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend. 2003 May 1;70(1):85–91. Exclusion Code: X8. [PubMed: 12681528]

51.

Caputo F, Addolorato G, Stoppo M, et al. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. Eur Neuropsychopharmacol. 2007 Dec;17(12):781–9. Exclusion Code: X5. [PubMed: 17611081]

52.

Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998 May;93(5):713–27. Exclusion Code: X5. [PubMed: 9692270]

53.

Carter AC, Miranda R, Gwaltney C, et al. Naltrexone's impact on alcohol expectancies in heavy drinkers. Alcoholism. 2010;34(6):177A. Exclusion Code: X3.

54.

Castro LA, Laranjeira R. [A double blind, randomized and placebo-controlled clinical trial with naltrexone and brief intervention in outpatient treatment of alcohol dependence]. J Bras Psiquiatr. 2009;58(2):79–85. CN-00754994. Exclusion Code: X1.

55.

Chen J, Johnson BA, Wang XQ, et al. Trajectory analyses in alcohol treatment research. Alcohol Clin Exp Res. 2012 Aug;36(8):1442–8. Exclusion Code: X6. [PMC free article: PMC3407320] [PubMed: 22525000]

56.

Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry. 1992 Jul;161:84–9. Exclusion Code: X8. [PubMed: 1638335]

57.

Christensen JK. Side-effects after Antabuse--myths or reality? Br J Clin Pract Suppl. 1984;36:21–8. Exclusion Code: X7. [PubMed: 6437426]

58.

Christensen JK, Ronsted P, Vaag UH. Side effects after disulfiram. Comparison of disulfiram and placebo in a double-blind multicentre study. Acta Psychiatr Scand. 1984 Apr;69(4):265–73. Exclusion Code: X9. [PubMed: 6372372]

59.

Ciraulo DA, Dong Q, Silverman BL, et al. Early treatment response in alcohol dependence with extended-release naltrexone. J Clin Psychiatry. 2008 Feb;69(2):190–5. Exclusion Code: X9. [PubMed: 18348601]

60.

Collins GB, Janesz JW, Byerly-Thrope J. The Cleveland Clinic Alcohol Rehabilitation Program: A treatment outcome study. A preliminary report. Cleve Clin Q. 1985;52(2):245–51. Exclusion Code: X4. [PubMed: 4028426]

61.

Connery H, Greenfield S, Livchits V, et al. Training and fidelity monitoring of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia: The IMPACT effectiveness trial. Subst Use Misuse. 2013;48(9):806–14. 2013-21629-011. First Author & Affiliation: Connery, Hilary. Exclusion Code: X5. [PMC free article: PMC4010131] [PubMed: 23750742]

62.

Corbin WR, Scott C, Leeman RF, et al. Early Subjective Response and Acquired Tolerance as Predictors of Alcohol Use and Related Problems in a Clinical Sample. Alcohol. 2013. Exclusion Code: X6. [PMC free article: PMC3586307] [PubMed: 23347236]

63.

Cornelius JR, Perkins KA, Salloum IM, et al. Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients. J Clin Psychopharmacol. 1999;19(2):183–4. Exclusion Code: X8. [PubMed: 10211921]

64.

Cornelius JR, Salloum IM, Cornelius MD, et al. Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacol Bull. 1995;31(2):297–303. Exclusion Code: X6. [PubMed: 7491382]

65.

Cornelius JR, Salloum IM, Ehler JG, et al. Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacol Bull. 1997;33(1):165–70. Exclusion Code: X8. [PubMed: 9133770]

66.

Cornelius JR, Salloum IM, Haskett RF, et al. Fluoxetine versus placebo in depressed alcoholics: a 1-year follow-up study. Addict Behav. 2000 Mar-Apr;25(2):307–10. Exclusion Code: X8. [PubMed: 10795957]

67.

Cornelius JR, Salloum IM, Thase ME, et al. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull. 1998;34(1):117–21. Exclusion Code: X8. [PubMed: 9564208]

68.

Cramer J, Rosenheck R, Kirk G, et al. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003 Sep-Oct;6(5):566–73. Exclusion Code: X6. [PubMed: 14627063]

69.

Critchfield GC, Eddy DM. A confidence profile analysis of the effectiveness of disulfiram in the treatment of chronic alcoholism. Med Care. 1987 Dec;25(12 Suppl):S66–75. Exclusion Code: X8. [PubMed: 3323686]

70.

Croissant B, Diehl A, Klein O, et al. A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. Alcohol Clin Exp Res. 2006 Apr;30(4):630–5. Exclusion Code: X5. [PubMed: 16573580]

71.

Croissant B, Klein O, Gehrlein L, et al. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry. 2006 Dec;21(8):570–3. Exclusion Code: X5. [PubMed: 17161284]

72.

Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997 Dec;54(12):1130–5. Exclusion Code: X5. [PubMed: 9400350]

73.

Cutler RB. Abatement of craving in recovering alcoholics: A descriptive analysis. Addict Res Theory. 2005;13(2):111–27. Exclusion Code: X6.

74.

Davidson D, Saha C, Scifres S, et al. Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers. Addict Behav. 2004 Aug;29(6):1253–8. Exclusion Code: X3. [PubMed: 15236831]

75.

Davidson D, Wirtz PW, Gulliver SB, et al. Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment. Psychopharmacology (Berl). 2007 Sep;194(1):1–10. Exclusion Code: X8. [PubMed: 17514344]

76.

DiClemente CC, Doyle SR, Donovan D. Predicting treatment seekers' readiness to change their drinking behavior in the COMBINE study. Alcohol. 2009;33(5):879–92. Exclusion Code: X4. [PMC free article: PMC2954369] [PubMed: 19320633]

77.

Diehl A, Ulmer L, Mutschler J, et al. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. Alcohol Alcohol. 2010 May-Jun;45(3):271–7. Exclusion Code: X8. [PubMed: 20348436]

78.

Dinh-Zarr Tho B, Goss Cynthia W, Heitman E, et al. Interventions for preventing injuries in problem drinkers. Cochrane Database Syst Rev. 2004;(3):CD001857. Exclusion Code: X4. [PMC free article: PMC7025439] [PubMed: 15266456]

79.

Dongier M. What treatment options exist for alcohol abuse? J Psychiatry Neurosci. 2003 Jan;28(1):80. Exclusion Code: X2. [PMC free article: PMC161728] [PubMed: 12587852]

80.

Donovan D, Mattson ME, Cisler RA, et al. Quality of life as an outcome measure in alcoholism treatment research. J Stud Alcohol. 2005;66(SUPPL. 15):119–39. Exclusion Code: X5. [PubMed: 16223064]

81.

Doty P, De Wit H. Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behav Pharmacol. 1995;6(4):386–94. Exclusion Code: X3. [PubMed: 11224347]

82.

Drake RE, Mercer-McFadden C, Mueser KT, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders (Structured abstract). Schizophr Bull. 1998:589–608. Exclusion Code: X2. [PubMed: 9853791]

83.

Drobes DJ, Anton RF. Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol. 2000 Mar;61(2):220–4. Exclusion Code: X7. [PubMed: 10757131]

84.

Drobes DJ, Anton RF, Thomas SE, et al. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003 Apr;28(4):755–64. Exclusion Code: X7. [PubMed: 12655322]

85.

Drtil J. Placebo therapy of alcohol dependent persons. Homeost Health Dis. 1997;38(4) Exclusion Code: X2.

86.

Duckert F, Johnsen J. Behavioral use of disulfiram in the treatment of problem drinking. Int J Addict. 1987 May;22(5):445–54. Exclusion Code: X8. [PubMed: 3596857]

87.

Dundon W, Lynch KG, Pettinati HM, et al. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol Clin Exp Res. 2004 Jul;28(7):1065–73. Exclusion Code: X8. [PMC free article: PMC1435448] [PubMed: 15252293]

88.

Epstein EE, Rhines KC, Cook S, et al. Changes in alcohol craving and consumption by phase of menstrual cycle in alcohol dependent women. J Subst Use. 2006;11(5):323–32. Exclusion Code: X4.

89.

Eriksson M, Berggren U, Blennow K, et al. Further investigation of citalopram on alcohol consumption in heavy drinkers: responsiveness possibly linked to the DRD2 A2/A2 genotype. Alcohol. 2001 May;24(1):15–23. Exclusion Code: X9. [PubMed: 11524178]

90.

Falk D, Wang XQ, Liu L, et al. Percentage of subjects with no heavy drinking days: Evaluation as an efficacy endpoint for alcoholclinical trials. Alcohol. 2010;34(12):2022–34. Exclusion Code: X6. [PubMed: 20659066]

91.

Fantozzi R, Caramelli L, Ledda F, et al. Biological markers and therapeutic outcome in alcoholic disease: a twelve-year survey. Klin Wochenschr. 1987 Jan 5;65(1):27–33. Exclusion Code: X4. [PubMed: 3560786]

92.

Farren CK, O'Malley SS. Occurrence and management of depression in the context of naltrexone treatment of alcoholism. Am J Psychiatry. 1999 Aug;156(8):1258–62. Exclusion Code: X8. [PubMed: 10450269]

93.

Farwell WR, Stump TE, Wang J, et al. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med. 2004;19(12):1200–5. Exclusion Code: X3. [PMC free article: PMC1492596] [PubMed: 15610330]

94.

Feeney GF, Connor JP, Mc DYR, et al. Is acamprosate use in alcohol dependence treatment reflected in improved subjective health status outcomes beyond cognitive behavioural therapy alone? J Addict Dis. 2006;25(4):49–58. Exclusion Code: X5. [PubMed: 17088225]

95.

Feeney GF, Connor JP, Young RM, et al. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006 May-Jun;41(3):321–7. Exclusion Code: X8. [PubMed: 16467406]

96.

Feinn R, Tennen H, Cramer J, et al. Measurement and prediction of medication compliance in problem drinkers. Alcohol Clin Exp Res. 2003 Aug;27(8):1286–92. Exclusion Code: X6. [PubMed: 12966323]

97.

Fernandez Miranda JJ, Marina Gonzalez PA, Montes Perez M, et al. Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12 month follow-up study. Actas Esp Psiquiatr. 2007 Jul-Aug;35(4):236–42. Exclusion Code: X5. [PubMed: 17592785]

98.

Finigan MW, Perkins T, Zold-Kilbourn P, et al. Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts. J Subst Abuse Treat. 2011 Oct;41(3):288–93. Exclusion Code: X8. [PubMed: 21696912]

99.

Flannery BA, Poole SA, Gallop RJ, et al. Alcohol craving predicts drinking during treatment: an analysis of three assessment instruments. J Stud Alcohol. 2003 Jan;64(1):120–6. Exclusion Code: X5. [PubMed: 12608492]

100.

Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999 Aug;23(8):1289–95. Exclusion Code: X6. [PubMed: 10470970]

101.

Foa EB, Yusko DA, McLean CP, et al. Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. JAMA. 2013 Aug 7;310(5):488–95. Exclusion Code: X8. [PubMed: 23925619]

102.

Fox HC, Anderson GM, Tuit K, et al. Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res. 2012 Feb;36(2):351–60. Exclusion Code: X6. [PMC free article: PMC3243763] [PubMed: 21919922]

103.

Freeman SA. Focus on time-sensitive factors that may respond to treatment. Curr Psychiatry. 2012;11(1):53–7. Exclusion Code: X8.

104.

Frick KM, Loessl B, Brueck RK, et al. What works for patients in outpatient treatment for alcohol addiction? an explorative study into clients' evaluation of subjective factors and therapy satisfaction. Subst Abuse. 2011;5(1):27–34. Exclusion Code: X6. [PMC free article: PMC3411521] [PubMed: 22879748]

105.

Friedmann PD, Mello D, Lonergan S, et al. Aversion to injection limits acceptability of extended-release naltrexone among homeless, alcohol-dependent patients. Substance Abuse. 2013;34(2):94–6. First Author & Affiliation: Friedmann, Peter D. Exclusion Code: X5. [PMC free article: PMC4394196] [PubMed: 23577900]

106.

Friedmann PD, Mello D, Lonergan S, et al. Aversion to injection limits acceptability of extended-release naltrexone among homeless, alcohol-dependent patients. Substance Abuse. 2013;34(2):94–6. 2013-13571-004. First Author & Affiliation: Friedmann, Peter D. Exclusion Code: X8. [PMC free article: PMC4394196] [PubMed: 23577900]

107.

Fucito LM, Toll BA, Wu R, et al. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl). 2011 Jun;215(4):655–63. Exclusion Code: X5. [PMC free article: PMC3645986] [PubMed: 21221531]

108.

Fuller R, Roth H, Long S. Compliance with disulfiram treatment of alcoholism. J Chronic Dis. 1983;36(2):161–70. Exclusion Code: X6. [PubMed: 6337171]

109.

Fuller RK, Williford WO, Lee KK, et al. Veterans Administration cooperative study of disulfiram in the treatment of alcoholism: study design and methodological considerations. Control Clin Trials. 1984 Sep;5(3):263–73. Exclusion Code: X2. [PubMed: 6386330]

110.

Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007 Nov;68(11):1691–700. Exclusion Code: X9. [PubMed: 18052562]

111.

Gache P, Hadengue A. Baclofen improves abstinence in alcoholic cirrhosis: Still better to come? J Hepatol. 2008;49(6):1083–5. Exclusion Code: X2. [PubMed: 18930331]

112.

Galarza NJ, Diaz Ramirez D, Guzman F, et al. The use of naltrexone to treat ambulatory patients with alcohol dependence. Bol Asoc Med P R. 1997 Oct-Dec;89(10-12):157–60. Exclusion Code: X9. [PubMed: 9577049]

113.

Gallant D. Reduction of ethanol intake by pharmacologic agents--investigational problems. Alcohol Clin Exp Res. 1992 Aug;16(4):836–7. Exclusion Code: X2. [PubMed: 1530148]

114.

Gamburg AL, Aranovich AG, Rasnyuk VA, et al. Some aspects of contemporary treatment of chronic alcoholics. Soviet Neurology & Psychiatry. 1984;17(2):50–7. Exclusion Code: X8.

115.

Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999 Apr 14;281(14):1318–25. Exclusion Code: X10. [PubMed: 10208148]

116.

Geerlings P, Ansoms C, Van DBW. Acamprosate and relapse prevention in outpatient alcoholics; results from a randomized, placebo-controlled double-blind study in the Benelux. Tijdschrift Voor Alcohol, Drugs En Andere Psychotrope Stoffen. 1995;21(3):129–41. CN-00170357. Exclusion Code: X1.

117.

George DT, Phillips MJ, Lifshitz M, et al. Fluoxetine treatment of alcoholic perpetrators of domestic violence: A 12-week, double-blind, randomized, placebo-controlled intervention study. J Clin Psychiatry. 2011;72(1):60–5. Exclusion Code: X6. [PMC free article: PMC3026856] [PubMed: 20673556]

118.

Gerra G, Caccavari R, Delsignore R, et al. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Curr Ther Res Clin Exp. 1992;52(2):291–5. Exclusion Code: X8.

119.

Goldstein MZ, Pataki A, Webb MT. Alcoholism among elderly persons. Psychiatr Serv. 1996 Sep;47(9):941–3. Exclusion Code: X2. [PubMed: 8875656]

120.

Goodwin FK. From the Alcohol, Drug Abuse, and Mental Health Administration. JAMA. 1990 Mar 23-30;263(12):1610. Exclusion Code: X3. [PubMed: 2155326]

121.

Gopalakrishnan R, Ross J, O'Brien C, et al. Course of late-life depression with alcoholism following combination therapy. J Stud Alcohol Drugs. 2009 Mar;70(2):237–41. Exclusion Code: X5. [PMC free article: PMC2653609] [PubMed: 19261235]

122.

Goyer PF, Major LF. Hepatotoxicity in disulfiram-treated patients. J Stud Alcohol. 1979;40(1):133–7. Exclusion Code: X7. [PubMed: 449328]

123.

Graf M. Pharmacological treatments at the East Kent Alcohol Service. Neuropsychopharmacol Hung. 2012;14:38. Exclusion Code: X8.

124.

Grassi MC, Cioce AM, Giudici FD, et al. Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: A pilot study. Pharmacol Res. 2007;55(2):117–21. Exclusion Code: X9. [PubMed: 17174102]

125.

Gross CM, Spiegelhalder K, Mercak J, et al. Predictability of alcohol relapse by hippocampal volumetry and psychometric variables. Psychiatry Res. 2013 Apr 30;212(1):14–8. Exclusion Code: X8. [PubMed: 23473987]

126.

Guardia J, Roncero C, Galan J, et al. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. Addict Behav. 2011 Mar;36(3):265–9. Exclusion Code: X5. [PubMed: 21146937]

127.

Gueorguieva R, Wu R, Donovan D, et al. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug Alcohol Depend. 2010 Mar 1;107(2-3):221–9. Exclusion Code: X6. [PMC free article: PMC2821955] [PubMed: 19969427]

128.

Gueorguieva R, Wu R, Pittman B, et al. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry. 2007 Jun 1;61(11):1290–5. Exclusion Code: X8. [PMC free article: PMC1952242] [PubMed: 17224132]

129.

Guerrini I, Gentili C, Nelli G, et al. A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence. Subst Abuse Treat Prev Policy. 2006;1:35. Exclusion Code: X4. [PMC free article: PMC1764726] [PubMed: 17176456]

130.

Guglielmo R, Martinotti G, Clerici M, et al. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012 Nov;29(11):947–57. Exclusion Code: X4. [PubMed: 23132700]

131.

Hameedi FA, Rosen MI, McCance-Katz EF, et al. Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry. 1995 Apr 15;37(8):560–3. Exclusion Code: X7. [PubMed: 7619981]

132.

Hammarberg A, Jayaram-Lindstrom N, Beck O, et al. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl). 2009 Jul;205(1):53–62. Exclusion Code: X9. [PubMed: 19319508]

133.

Hammarberg A, Nylander I, Zhou Q, et al. The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin. Brain Res. 2009 Dec 11;1305(Suppl):S2–6. Exclusion Code: X9. [PubMed: 19799882]

134.

Hasin DS, Endicott J, Keller MB. Alcohol problems in psychiatric patients: 5-year course. Compr Psychiatry. 1991 Jul-Aug;32(4):303–16. Exclusion Code: X4. [PubMed: 1935019]

135.

Hernandez-Avila CA, Burleson JA, Kranzler HR. Stage of change as a predictor of abstinence among alcohol-dependent subjects in pharmacotherapy trials. Substance Abuse. 1998;19(2):81–91. Exclusion Code: X6. [PubMed: 12511809]

136.

Hernandez-Avila CA, Song C, Kuo L, et al. Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res. 2006 May;30(5):860–5. Exclusion Code: X9. [PubMed: 16634855]

137.

Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl). 1998 Sep;139(1-2):44–52. Exclusion Code: X9. [PubMed: 9768541]

138.

Higgins ST, Budney AJ, Bickel WK, et al. Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry. 1993;150(4):675–6. Exclusion Code: X8. [PubMed: 8465895]

139.

Hobbs JD, Kushner MG, Lee SS, et al. Meta-analysis of supplemental treatment for depressive and anxiety disorders in patients being treated for alcohol dependence (Structured abstract). Am J Addict. 2011:319–29. Exclusion Code: X8. [PMC free article: PMC3124006] [PubMed: 21679263]

140.

Howland RH, Rush AJ, Wisniewski SR, et al. Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome. Drug Alcohol Depend. 2009;99(1-3):248–60. Exclusion Code: X3. [PubMed: 18986774]

141.

Hunter-Reel D, Witkiewitz K, Zweben A. Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders? Alcohol Clin Exp Res. 2012 Jul;36(7):1237–43. Exclusion Code: X6. [PMC free article: PMC3366157] [PubMed: 22324565]

142.

Hussar DA. New drugs: acamprosate calcium and solifenacin succinate. J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):109–11. Exclusion Code: X2. [PubMed: 15730126]

143.

Hutchison KE, Wooden A, Swift RM, et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003 Oct;28(10):1882–8. Exclusion Code: X7. [PubMed: 12888781]

144.

Ionescu R. Lithium salts in alcohol addiction therapy. Revue Roumaine de Neurologie et Psychiatrie. 1985;23(1):3–10. Exclusion Code: X8. [PubMed: 3920750]

145.

Ivanets NN, Anokhina IP, Kogan BM, et al. [The efficacy and mechanisms of action of lerivon in alcoholism]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko? promyshlennosti Rossi?sko? Federatsii, Vserossi?skoe obshchestvo nevrologov [i] Vserossi?skoe obshchestvo psikhiatrov. 1996;96(5):52–8. CN-00134237. Exclusion Code: X1. [PubMed: 9012256]

146.

Jaffe AJ, Rounsaville B, Chang G, et al. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol. 1996 Oct;64(5):1044–53. Exclusion Code: X6. [PubMed: 8916634]

147.

Janiri L, Gobbi G, Mannelli P, et al. Effects of fluoxetine and antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol. 1996;11(2):109–17. Exclusion Code: X9. [PubMed: 8803648]

148.

Janiri L, Gobbi G, Mannelli P, et al. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol. 1996 Jun;11(2):109–17. Exclusion Code: X9. [PubMed: 8803648]

149.

Janiri L, Martinotti G, Di Nicola M. Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: Results from a pilot study. J Clin Psychopharmacol. 2007;27(5):519–20. Exclusion Code: X5. [PubMed: 17873691]

150.

Jensen SB, Christoffersen CB, Noerregaard A. Apomorphine in outpatient treatment of alcohol intoxication and abstinence: a double-blind study. Br J Addict Alcohol Other Drugs. 1977 Dec;72(4):325–30. Exclusion Code: X4. [PubMed: 341937]

151.

Johnsen J, Morland J. Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome. Alcohol Clin Exp Res. 1991 Jun;15(3):532–6. Exclusion Code: X4. [PubMed: 1877740]

152.

Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate was effective as an adjunt to standardised medication compliance management in alcohol dependence. Evid-Based Med. 2004;9(1):24. Exclusion Code: X2.

153.

Johnson BA, Ait-Daoud N, Ma JZ, et al. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. Alcohol Clin Exp Res. 2003 Nov;27(11):1773–9. Exclusion Code: X6. [PubMed: 14634493]

154.

Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res. 2000 May;24(5):737–42. Exclusion Code: X4. [PubMed: 10832917]

155.

Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011 Mar;168(3):265–75. Exclusion Code: X9. [PMC free article: PMC3063997] [PubMed: 21247998]

156.

Johnson BA, O'Malley SS, Ciraulo DA, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol. 2003 Jun;23(3):281–93. Exclusion Code: X8. [PubMed: 12826990]

157.

Johnson BA, Roache JD, Ait-Daoud N, et al. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl). 2002 Apr;160(4):408–13. Exclusion Code: X6. [PubMed: 11919668]

158.

Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000 Aug 23-30;284(8):963–71. Exclusion Code: X9. [PubMed: 10944641]

159.

Johnson BA, Seneviratne C, Wang XQ, et al. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry. 2013 Sep 1;170(9):1020–31. Exclusion Code: X9. [PMC free article: PMC3809153] [PubMed: 23897038]

160.

Johnson JL, Wiechelt SA, Ahmed AU, et al. Outcomes for substance user treatment in women: Results from the Baltimore Drug and Alcohol Treatment Outcomes Study. Subst Use Misuse. 2003;38(11-13):1807–29. +920-922. Exclusion Code: X3. [PubMed: 14582579]

161.

Kampman KM, Pettinati HM, Lynch KG, et al. Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav. 2009 Jun-Jul;34(6-7):581–6. Exclusion Code: X5. [PMC free article: PMC2729436] [PubMed: 19345510]

162.

Karam-Hage M, Brower KJ. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003;57(5):542–4. Exclusion Code: X8. [PMC free article: PMC2967491] [PubMed: 12950711]

163.

Kenna GA, Zywiak WH, McGeary JE, et al. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res. 2009 Feb;33(2):315–23. Exclusion Code: X9. [PMC free article: PMC5567679] [PubMed: 19032576]

164.

Kiec-Swierczynska M, Krecisz B, Fabicka B. Systemic contact dermatitis from implanted disulfiram. Contact Dermatitis. 2000 Oct;43(4):246–7. Exclusion Code: X8. [PubMed: 11011945]

165.

Kiefer F, Jahn H, Holzbach R, et al. The NALCAM-study: Efficacy, tolerability, outcome. Sucht. 2003;49(6):342–51. CN-00475102. Exclusion Code: X1.

166.

Kiefer F, Jahn H, Otte C, et al. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? Biol Psychiatry. 2006 Jul 1;60(1):74–6. Exclusion Code: X6. [PubMed: 16483549]

167.

Kiefer F, Jimenez-Arriero MA, Klein O, et al. Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone. Addict Biol. 2008 Mar;13(1):124–9. Exclusion Code: X8. [PubMed: 17573782]

168.

King A, Cao D, Vanier C, et al. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. Alcohol Clin Exp Res. 2009 Jun;33(6):1044–50. Exclusion Code: X3. [PMC free article: PMC4625790] [PubMed: 19302083]

169.

King AC, Volpicelli JR, Frazer A, et al. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl). 1997 Jan;129(1):15–22. Exclusion Code: X7. [PubMed: 9122358]

170.

Kingsbury SJ, Salzman C. Disulfiram in the treatment of alcoholic patients with schizophrenia. Hosp Community Psychiatry. 1990;41(2):133–4. Exclusion Code: X2. [PubMed: 2303214]

171.

Kiritze-Topor P, Huas D, Rosenzweig C, et al. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care. Alcohol Alcohol. 2004 Nov-Dec;39(6):520–7. Exclusion Code: X5. [PubMed: 15304381]

172.

Knox PC, Donovan DM. Using naltrexone in inpatient alcoholism treatment. J Psychoactive Drugs. 1999 Oct-Dec;31(4):373–88. Exclusion Code: X7. [PubMed: 10681104]

173.

Knox WJ. Four-year follow-up of veterans treated on a small alcoholism treatment ward. Q J Stud Alcohol. 1972 Mar;33(1):105–10. Exclusion Code: X5. [PubMed: 4551019]

174.

Koeter MW, van den Brink W, Lehert P. Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence. J Subst Abuse Treat. 2010 Oct;39(3):218–26. Exclusion Code: X8. [PubMed: 20627222]

175.

Koski A, Ojanpera I, Vuori E. Interaction of alcohol and drugs in fatal poisonings. Hum Exp Toxicol. 2003 May;22(5):281–7. Exclusion Code: X8. [PubMed: 12774892]

176.

Krampe H, Stawicki S, Wagner T, et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res. 2006 Jan;30(1):86–95. Exclusion Code: X8. [PubMed: 16433735]

177.

Kranzler HR, Armeli S, Feinn R, et al. Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers. J Consult Clin Psychol. 2004 Apr;72(2):317–27. Exclusion Code: X9. [PubMed: 15065964]

178.

Kranzler HR, Armeli S, Tennen H, et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol. 2003 Jun;23(3):294–304. Exclusion Code: X9. [PubMed: 12826991]

179.

Kranzler HR, Burleson JA, Brown J, et al. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996 Dec;20(9):1534–41. Exclusion Code: X6. [PubMed: 8986200]

180.

Kranzler HR, Del Boca F, Korner P, et al. Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism. J Subst Abuse Treat. 1993 May-Jun;10(3):283–7. Exclusion Code: X8. [PubMed: 8315702]

181.

Kranzler HR, Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict. 2008 Jan-Feb;17(1):70–6. Exclusion Code: X8. [PubMed: 18214726]

182.

Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res. 1998 Aug;22(5):1074–9. Exclusion Code: X9. [PubMed: 9726277]

183.

Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology. 2000 May;22(5):493–503. Exclusion Code: X9. [PubMed: 10731624]

184.

Kranzler HR, Mueller T, Cornelius J, et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2006 Feb;26(1):13–20. Exclusion Code: X9. [PubMed: 16415699]

185.

Kranzler HR, Pierucci-Lagha A, Feinn R, et al. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res. 2003 Jul;27(7):1150–5. Exclusion Code: X5. [PubMed: 12878921]

186.

Kranzler HR, Tennen H, Penta C, et al. Targeted naltrexone treatment of early problem drinkers. Addict Behav. 1997 May-Jun;22(3):431–6. Exclusion Code: X5. [PubMed: 9183513]

187.

Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcohol. 2001;25(9):1335–41. Exclusion Code: X8. [PubMed: 11584154]

188.

Kravitz HM, Fawcett J, McGuire M, et al. Treatment attrition among alcohol-dependent men: is it related to novelty seeking personality traits? J Clin Psychopharmacol. 1999 Feb;19(1):51–6. Exclusion Code: X6. [PubMed: 9934943]

189.

Krupitski EM, Burakov AM, Ivanov VB, et al. [The use of baclofen for treating affective disorders in alcoholism]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko? promyshlennosti Rossi?sko? Federatsii, Vserossi?skoe obshchestvo nevrologov [i] Vserossi?skoe obshchestvo psikhiatrov. 1994;94(1):57–61. CN-00102296. Exclusion Code: X1. [PubMed: 8009935]

190.

Krupitsky EM, Burakov AM, Ivanov VB, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend. 1993 Sep;33(2):157–63. Exclusion Code: X6. [PubMed: 8261880]

191.

Krylov EN. Psychotropic activity of the antialcohol preparation Proproten-100. Bull Exp Biol Med. 2003 Jan;135 Suppl 7:176–80. Exclusion Code: X3. [PubMed: 12949691]

192.

Krystal JH, Gueorguieva R, Cramer J, et al. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: Results from VA cooperative study no. 425, “naltrexone in the treatment of alcoholism” Alcohol. 2008;32(1):85–91. Exclusion Code: X8. [PubMed: 18070245]

193.

Labbate LA, Sonne SC, Randal CL, et al. Does comorbid anxiety or depression affect clinical outcomes in patients with post-traumatic stress disorder and alcohol use disorders? Compr Psychiatry. 2004 Jul-Aug;45(4):304–10. Exclusion Code: X6. [PubMed: 15224273]

194.

Ladewig D, Knecht T, Leher P, et al. [Acamprosate--a stabilizing factor in long-term withdrawal of alcoholic patients]. Therapeutische Umschau. Revue thérapeutique. 1993;50(3):182–8. Exclusion Code: X1. [PubMed: 8475472]

195.

Lake CR, Major LF, Ziegler MG, et al. Increased sympathetic nervous system activity in alcoholic patients treated with disulfiram. Am J Psychiatry. 1977 Dec;134(12):1411–4. Exclusion Code: X7. [PubMed: 920841]

196.

Landabaso MA, Iraurgi I, Sanz J, et al. Naltrexone in the treatment of alcoholism. Two-year follow up results. Eur J Psychiat. 1999;13(2):97–105. Exclusion Code: X4.

197.

Lapham S, Forman R, Alexander M, et al. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients. J Subst Abuse Treat. 2009 Jan;36(1):1–6. Exclusion Code: X6. [PubMed: 18775624]

198.

Leggio L, Ferrulli A, Zambon A, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012 Apr;37(4):561–4. Exclusion Code: X8. [PMC free article: PMC4975777] [PubMed: 22244707]

199.

Lesch OM, Riegler A, Gutierrez K, et al. The European acamprosate trials: Conclusions for research and therapy. J Biomed Sci. 2001;8(1):89–95. Exclusion Code: X2. [PubMed: 11173981]

200.

Lesch OM, Walter H. Subtypes of alcoholism and their role in therapy. Alcohol Alcohol. 1996;31(Suppl 1):63–7. Exclusion Code: X2. [PubMed: 8737003]

201.

Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review (Structured abstract). QJM. 2007;100(7):395–404. DARE-12007002731. Exclusion Code: X2. [PubMed: 17566010]

202.

Lewis DC. The clinical usefulness of narcotic antagonists: preliminary findings on the use of naltrexone. Am J Drug Alcohol Abuse. 1975;2(3-4):403–15. Exclusion Code: X5. [PubMed: 1227300]

203.

Liebson I, Bigelow G. A behavioural-pharmacological treatment of dually addicted patients. Behav Res Ther. 1972 Nov;10(4):403–5. Exclusion Code: X5. [PubMed: 4637497]

204.

Likhitsathian S, Saengcharnchai P, Uttawichai K, et al. Cognitive changes in topiramate-treated patients with alcoholism: a 12-week prospective study in patients recently detoxified. Psychiatry Clin Neurosci. 2012 Apr;66(3):235–41. Exclusion Code: X5. [PubMed: 22443246]

205.

Litten RZ, Fertig JB, Falk DE, et al. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012 Mar;36(3):406–16. Exclusion Code: X9. [PMC free article: PMC3248956] [PubMed: 21950727]

206.

Loo H, Malka R, Defrance R, et al. Tianeptine and amitriptyline. Controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology. 1988;19(2):79–85. Exclusion Code: X9. [PubMed: 3067116]

207.

Luggen AS. Alcohol and the older adult. Adv Nurse Pract. 2006 Jan;14(1):47–52. Exclusion Code: X2. [PubMed: 16425516]

208.

Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013 Feb;108(2):275–93. Exclusion Code: X8. [PMC free article: PMC3970823] [PubMed: 23075288]

209.

Malcolm R, Myrick LH, Veatch LM, et al. Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. J Clin Sleep Med. 2007 Feb 15;3(1):24–32. Exclusion Code: X3. [PubMed: 17557449]

210.

Malec TS, Malec EA, Dongier M. Efficacy of buspirone in alcohol dependence: A review. Alcoholism. 1996;20(5):853–8. Exclusion Code: X2. [PubMed: 8865960]

211.

Malla A. An outcome study comparing refusers and acceptors of treatment for alcoholism. Can J Psychiatry. 1988 Apr;33(3):183–7. Exclusion Code: X3. [PubMed: 3383091]

212.

Mann K, Kiefer F, Smolka M, et al. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Alcohol Clin Exp Res. 2009 Apr;33(4):674–83. Exclusion Code: X8. [PubMed: 19170666]

213.

Mao YM, Zeng MD, Li YM, et al. [Capsule metadoxine in the treatment of alcoholic liver disease: a randomized, double-blind, placebo-controlled, multicenter study]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi. [Chinese journal of hepatology]. 2009;17(3):213–6. Exclusion Code: X1. [PubMed: 19335986]

214.

Maremmani AGI, Pani PP, Rovai L, et al. Long-term (gamma)-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics. Int J Environmen Res Public Health. 2011;8(7):2816–27. Exclusion Code: X4. [PMC free article: PMC3155331] [PubMed: 21845160]

215.

Marrazzi MA, Wroblewski JM, Kinzie J, et al. High-dose naltrexone and liver function safety. Am J Addict. 1997;6(1):21–9. Exclusion Code: X3. [PubMed: 9097868]

216.

Martin PR, Adinoff B, Lane E, et al. Fluvoxamine treatment of alcoholic amnestic disorder. Eur Neuropsychopharmacol. 1995 Mar;5(1):27–33. Exclusion Code: X3. [PubMed: 7542052]

217.

Martin PR, Loewy J, Liou S, et al. Correlation of Serum Gamma-Glutamyl Transferase With Alcohol Consumption; 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, GA. 2005. p. Nr215. Exclusion Code: X6.

218.

Martinotti G, Di Nicola M, Romanelli R, et al. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol. 2007 Apr;22(3):149–56. Exclusion Code: X5. [PubMed: 17397097]

219.

Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol. 2010 Sep;24(9):1367–74. Exclusion Code: X5. [PubMed: 19346279]

220.

Mason BJ, Kocsis JH. Desipramine treatment of alcoholism. Psychopharmacol Bull. 1991;27(2):155–61. Exclusion Code: X6. [PubMed: 1924663]

221.

Mason BJ, Lehert P. Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy. J Addict Med. 2009;3(3):164–71. Exclusion Code: X8. [PubMed: 21769013]

222.

Mason BJ, Light JM, Williams LD, et al. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol. 2009 Jan;14(1):73–83. Exclusion Code: X6. [PMC free article: PMC2758315] [PubMed: 18855801]

223.

McGeary JE, Monti PM, Rohsenow DJ, et al. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006 Aug;30(8):1288–96. Exclusion Code: X3. [PubMed: 16899031]

224.

McKee SA, Harrison EL, O'Malley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009 Jul 15;66(2):185–90. Exclusion Code: X7. [PMC free article: PMC2863311] [PubMed: 19249750]

225.

McKee SA, Young-Wolff KC, Harrison ELR, et al. Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country Survey. Alcohol. 2013;37(5):804–10. 2013-15234-013. First Author & Affiliation: McKee, Sherry A. Exclusion Code: X8. [PMC free article: PMC3610791] [PubMed: 23240586]

226.

McRae-Clark AL, Verduin ML, Tolliver BK, et al. An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy. J Dual Diagn. 2009;5(1):83–96. Exclusion Code: X5.

227.

Meszaros K, Willinger U, Fischer G, et al. The tridimensional personality model: influencing variables in a sample of detoxified alcohol dependents. European Fluvoxamine in Alcoholism Study Group. Compr Psychiatry. 1996 Mar-Apr;37(2):109–14. Exclusion Code: X6. [PubMed: 8654059]

228.

Minuk GY, Rockman GE, German GB, et al. The use of sodium valproate in the treatment of alcoholism. J Addict Dis. 1995;14(2):67–74. Exclusion Code: X8. [PubMed: 8541361]

229.

Miranda R, MacKillop J, Meehan J, et al. Biobehavioral effects of topiramate among heavy drinkers. Alcoholism. 2011;35:21A. Exclusion Code: X3.

230.

Miranda R Jr., MacKillop J, Monti PM, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008 Mar;32(3):489–97. Exclusion Code: X3. [PubMed: 18215213]

231.

Miranda R, Ray L, Reynolds E, et al. Effects of naltrexone on adolescent drinking. Alcoholism. 2012;36:89A. Exclusion Code: X3.

232.

Mitchell JM, Fields HL, White RL, et al. The Asp40 μ-Opioid Receptor Allele Does Not Predict Naltrexone Treatment Efficacy in Heavy Drinkers. J Clin Psychopharmacol. 2007;27(1):112–5. Exclusion Code: X3. [PubMed: 17224736]

233.

Mitchell JM, Teague CH, Kayser AS, et al. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl). 2012 Oct;223(3):299–306. Exclusion Code: X3. [PMC free article: PMC3438402] [PubMed: 22547331]

234.

Moak DH, Anton RF, Malcolm R, et al. Alcoholic subjects with anxiety disorder: Characteristics of completers and noncompleters in a pharmacologic study. Am J Addict. 1993;2(1):39–47. Exclusion Code: X4.

235.

Monahan SC, Finney JW. Explaining abstinence rates following treatment for alcohol abuse: a quantitative synthesis of patient, research design and treatment effects (Structured abstract). Addiction. 1996:787–805. Exclusion Code: X10. [PubMed: 8696243]

236.

Monnelly EP, Ciraulo DA, Knapp C, et al. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol. 2004 Oct;24(5):532–5. Exclusion Code: X5. [PubMed: 15349010]

237.

Monnelly EP, LoCastro JS, Gagnon D, et al. Quetiapine versus trazodone in reducing rehospitalization for alcohol dependence: A large data-base study. J Addict Med. 2008;2(3):128–34. Exclusion Code: X8. [PubMed: 21768982]

238.

Monti PM, Rohsenow DJ. Coping-skills training and cue-exposure therapy in the treatment of alcoholism. Alcohol Research & Health. 1999;23(2):107–15. Exclusion Code: X2. [PMC free article: PMC6760423] [PubMed: 10890804]

239.

Morgan MY, Landron F, Lehert P. Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support. Alcohol Clin Exp Res. 2004 Jan;28(1):64–77. Exclusion Code: X5. [PubMed: 14745303]

240.

Mueser KT, Noordsy DL, Fox L, et al. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict. 2003 May-Jun;12(3):242–52. Exclusion Code: X8. [PubMed: 12851020]

241.

Muhonen LH, Lahti J, Alho H, et al. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence. Psychiatry Res. 2011 Mar 30;186(1):53–7. Exclusion Code: X6. [PubMed: 20800901]

242.

Muhonen LH, Lahti J, Sinclair D, et al. Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy. 2008;3:20. Exclusion Code: X5. [PMC free article: PMC2569922] [PubMed: 18834506]

243.

Muhonen LH, Lonnqvist J, Juva K, et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008 Mar;69(3):392–9. Exclusion Code: X5. [PubMed: 18348597]

244.

Murthy KK, Praveenlal K. An experience with disulfiram in the management of Alcohol Dependence Syndrome: I. Side effects of disulfiram and symptoms of alcohol-disulfiram reaction. Ind J Psychol Med. 1988;11(2):145–8. Exclusion Code: X5.

245.

Myrick H, Anton R, Voronin K, et al. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res. 2007 Feb;31(2):221–7. Exclusion Code: X7. [PubMed: 17250613]

246.

Myrick H, Li X, Randall PK, et al. The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol. 2010 Aug;30(4):365–72. Exclusion Code: X9. [PMC free article: PMC3595185] [PubMed: 20571434]

247.

Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009 Sep;33(9):1582–8. Exclusion Code: X3. [PMC free article: PMC2769515] [PubMed: 19485969]

248.

Namkoong K, Lee BO, Lee PG, et al. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003 Mar-Apr;38(2):135–41. Exclusion Code: X9. [PubMed: 12634260]

249.

Naranjo CA, Kadlec KE, Sanhueza P, et al. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther. 1990 Apr;47(4):490–8. Exclusion Code: X9. [PubMed: 2328557]

250.

Naranjo CA, Knoke DM, Bremner KE. Variations in response to citalopram in men and women with alcohol dependence. J Psychiatry Neurosci. 2000 May;25(3):269–75. Exclusion Code: X8. [PMC free article: PMC1407711] [PubMed: 10863887]

251.

Naranjo CA, Poulos CX, Bremner KE, et al. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther. 1992 Jun;51(6):729–39. Exclusion Code: X7. [PubMed: 1535302]

252.

Naranjo CA, Poulos CX, Bremner KE, et al. Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol. 1994 Sep;9(3):163–72. Exclusion Code: X3. [PubMed: 7814825]

253.

Naranjo CA, Sellers EM, Sullivan JT, et al. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther. 1987 Mar;41(3):266–74. Exclusion Code: X3. [PubMed: 3469057]

254.

Neto D, Lambaz R, Tavares JE. Compliance with aftercare treatment, including disulfiram, and effect on outcome in alcohol-dependent patients. Alcohol Alcohol. 2007 Nov-Dec;42(6):604–9. Exclusion Code: X8. [PubMed: 17878216]

255.

Niederhofer H, Staffen W. Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry. 2003 Jun;12(3):144–8. Exclusion Code: X8. [PubMed: 12768462]

256.

Niederhofer H, Staffen W, Mair A. Comparison of naltrexone and placebo in treatment of alcohol dependence of adolescents. Alcohol Treat Q. 2003;21(2):87–95. Exclusion Code: X3.

257.

Nunes EV, Levin FR. Treatment of Depression in Patients with Alcohol or Other Drug Dependence: A Meta-analysis. JAMA. 2004;291(15):1887–96. Exclusion Code: X3. [PubMed: 15100209]

258.

Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry. 1993 Jun;150(6):963–5. Exclusion Code: X9. [PubMed: 8494079]

259.

O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996 Jan-Feb;13(1):35–9. Exclusion Code: X6. [PubMed: 8837932]

260.

O'Carroll RE, Moffoot AP, Ebmeier KP, et al. Effects of fluvoxamine treatment on cognitive functioning in the alcoholic Korsakoff syndrome. Psychopharmacology (Berl). 1994 Sep;116(1):85–8. Exclusion Code: X3. [PubMed: 7862935]

261.

Ojehagen A, Skjaerris A, Berglund M. Long-term use of aversive drugs in outpatient alcoholism treatment. Acta Psychiatr Scand. 1991 Aug;84(2):185–90. Exclusion Code: X5. [PubMed: 1950615]

262.

O'Malley S. Naltrexone for heavy drinking in young adults. Alcohol. 2012;36:334A. Exclusion Code: X3.

263.

O'Malley SS. Current strategies for the treatment of alcohol dependence in the United States. Drug Alcohol Depend. 1995;39(Suppl 1):S3–S7. Exclusion Code: X2. [PubMed: 8565795]

264.

O'Malley SS. Opioid antagonists in the treatment of alcohol dependence: Clinical efficacy and prevention of relapse. Alcohol Alcohol. 1996;31(Suppl 1):77–81. Exclusion Code: X2. [PubMed: 8737005]

265.

O'Malley SS, Croop RS, Wroblewski JM, et al. Naltrexone in the treatment of alcohol dependence: A combined analysis of two trials. Psychiatr Ann. 1995;25(11):681–8. Exclusion Code: X8.

266.

O'Malley SS, Garbutt JC, Gastfriend DR, et al. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol. 2007 Oct;27(5):507–12. Exclusion Code: X5. [PubMed: 17873686]

267.

O'Malley SS, Jaffe AJ, Rode S, et al. Experience of a ‘slip’ among alcoholics treated with naltrexone or placebo. Am J Psychiatry. 1996;153(2):281–3. Exclusion Code: X6. [PubMed: 8561215]

268.

O'Malley SS, Krishnan-Sarin S, McKee SA, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. Int J Neuropsychopharmacol. 2009 Jun;12(5):589–97. Exclusion Code: X3. [PMC free article: PMC3094855] [PubMed: 18796184]

269.

O'Malley SS, Rounsaville BJ, Farren C, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med. 2003 Jul 28;163(14):1695–704. Exclusion Code: X8. [PubMed: 12885685]

270.

Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology (Berl). 2001 Apr;154(4):397–402. Exclusion Code: X8. [PubMed: 11349393]

271.

Ooteman W, Naassila M, Koeter MW, et al. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328–37. Exclusion Code: X6. [PubMed: 19523047]

272.

Oroszi G, Anton RF, O'Malley S, et al. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res. 2009 Mar;33(3):383–93. Exclusion Code: X5. [PMC free article: PMC2679376] [PubMed: 19053977]

273.

Oslin D. OPRM1 sequence variation and clinical studies of alcohol dependent adults. Alcohol. 2011;35:314A. Exclusion Code: X8.

274.

Oslin D, Liberto JG, O'Brien J, et al. Tolerability of naltrexone in treating older, alcohol-dependent patients. Am J Addict. 1997 Summer;6(3):266–70. Exclusion Code: X6. [PubMed: 9256993]

275.

Oslin DW. Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatry. 2005 Jun;13(6):491–500. Exclusion Code: X4. [PMC free article: PMC3172720] [PubMed: 15956269]

276.

Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003 Aug;28(8):1546–52. Exclusion Code: X8. [PubMed: 12813472]

277.

Oslin DW, Pettinati H, Volpicelli JR. Alcoholism treatment adherence: older age predicts better adherence and drinking outcomes. Am J Geriatr Psychiatry. 2002 Nov-Dec;10(6):740–7. Exclusion Code: X8. [PubMed: 12427583]

278.

Palatty PL, Saldanha E. Status of disulfiram in present day alcoholic deaddiction therapy. Indian J Psychiatry. 2011;53(1):25–9. Exclusion Code: X5. [PMC free article: PMC3056183] [PubMed: 21431004]

279.

Palliyath S, Schwartz BD. Disulfiram neuropathy: electrophysiological study. Electromyogr Clin Neurophysiol. 1988 Jun-Jul;28(5):245–7. Exclusion Code: X6. [PubMed: 2847909]

280.

Paparrigopoulos T, Tzavellas E, Karaiskos D, et al. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41. Exclusion Code: X8. [PMC free article: PMC3062593] [PubMed: 21401921]

281.

Peachey JE, Zilm DH, Robinson GM, et al. A placebo-controlled double-blind comparative clinical study of the disulfiram- and calcium carbimide-acetaldehyde mediated ethanol reactions in social drinkers. Alcohol Clin Exp Res. 1983 Spring;7(2):180–7. Exclusion Code: X7. [PubMed: 6346921]

282.

Perugi G, Toni C, Frare F, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol. 2002 Dec;22(6):584–91. Exclusion Code: X3. [PubMed: 12454558]

283.

Peterson AM. Improving adherence in patients with alcohol dependence: A new role for pharmacists. Am J Health Syst Pharm. 2007;64(5 SUPPL.):S23–S9. Exclusion Code: X2. [PubMed: 17322179]

284.

Petrakis IL, Carroll KM, Nich C, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction. 2000;95(2):219–28. Exclusion Code: X3. [PubMed: 10723850]

285.

Pettinati HM, Dundon W, Lipkin C. Gender differences in response to sertraline pharmacotherapy in Type A alcohol dependence. Am J Addict. 2004 May-Jun;13(3):236–47. Exclusion Code: X8. [PubMed: 15370943]

286.

Pettinati HM, Kampman KM, Lynch KG, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav. 2008 May;33(5):651–67. Exclusion Code: X9. [PMC free article: PMC2374760] [PubMed: 18079068]

287.

Pettinati HM, O'Brien CP, Rabinowitz AR, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol. 2006 Dec;26(6):610–25. Exclusion Code: X10. [PubMed: 17110818]

288.

Pettinati HM, Silverman BL, Battisti JJ, et al. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res. 2011 Oct;35(10):1804–11. Exclusion Code: X8. [PubMed: 21575016]

289.

Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000 Jul;24(7):1041–9. Exclusion Code: X8. [PubMed: 10924008]

290.

Pettinati HM, Volpicelli JR, Pierce JD Jr., et al. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19(1):71–83. Exclusion Code: X8. [PubMed: 10772604]

291.

Ponce G, Sánchez-García J, Rubio G, et al. [Efficacy of naltrexone in the treatment of alcohol dependence disorder in women]. Actas españolas de psiquiatría. 2005;33(1):13–8. Exclusion Code: X1. [PubMed: 15704026]

292.

Pondé de-Sena E, Santos-Jesus R, Almeida Sarmento C, et al. Use of carbamazepine-buspirone combination in alcohol dependence. J Bras Psiquiatr. 1997;46(12):645–9. Exclusion Code: X1.

293.

Powell BJ, Penick EC, Read MR, et al. Comparison of three outpatient treatment interventions: a twelve-month follow-up of men alcoholics. J Stud Alcohol. 1985 Jul;46(4):309–12. Exclusion Code: X5. [PubMed: 2993750]

294.

Prisciandaro JJ, Brown DG, Brady KT, et al. Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry Res. 2011 Aug 15;188(3):361–5. Exclusion Code: X9. [PMC free article: PMC4750381] [PubMed: 21641663]

295.

Prisciandaro JJ, Desantis SM, Bandyopadhyay D. Simultaneous Modeling of the Impact of Treatments on Alcohol Consumption and Quality of Life in the COMBINE Study: A Coupled Hidden Markov Analysis. Alcohol. 2012;36(12):2141–9. Exclusion Code: X8. [PMC free article: PMC3416970] [PubMed: 22551231]

296.

Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery (Structured abstract). J Consult Clin Psychol. 2004:1144–56. Exclusion Code: X3. [PubMed: 15612860]

297.

Randall CL, Johnson MR, Thevos AK, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety. 2001;14(4):255–62. Exclusion Code: X9. [PubMed: 11754136]

298.

Ray LA, Hutchison KE, Bryan A. Psychosocial predictors of treatment outcome, dropout, and change processes in a pharmacological clinical trial for alcohol dependence. Addict Disord Their Treat. 2006;5(4):179–90. Exclusion Code: X6.

299.

Ray LA, Miranda R Jr., MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009 Apr;17(2):122–9. Exclusion Code: X9. [PMC free article: PMC3682424] [PubMed: 19331489]

300.

Ray LA, Oslin DW. Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. Drug Alcohol Depend. 2009 Dec 1;105(3):256–8. Exclusion Code: X5. [PMC free article: PMC3409877] [PubMed: 19717248]

301.

Reid SC, Teesson M, Sannibale C, et al. The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial. J Stud Alcohol. 2005 Nov;66(6):833–41. Exclusion Code: X5. [PubMed: 16459945]

302.

Richardson K, Baillie A, Reid S, et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction. 2008 Jun;103(6):953–9. Exclusion Code: X6. [PubMed: 18482418]

303.

Roache JD. L/S serotonin transporter polymorphism predicts serotonergic treatment outcome in alcohol dependence. Alcohol. 2011;35:339A. Exclusion Code: X9.

304.

Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res. 2000 Oct;24(10):1542–9. Exclusion Code: X6. [PubMed: 11045863]

305.

Roosa BA. Alcoholism treatment and medical utilization. US: ProQuest Information & Learning; 1986. Exclusion Code: X8.

306.

Rosenberg CM. Drug maintenance in the outpatient treatment of chronic alcoholism. Arch Gen Psychiatry. 1974 Mar;30(3):373–7. Exclusion Code: X8. [PubMed: 4813140]

307.

Rosenthal RN, Gage A, Perhach JL, et al. Acamprosate: Safety and tolerability in the treatment of alcohol dependence. J Addict Med. 2008;2(1):40–50. Exclusion Code: X8. [PubMed: 21768971]

308.

Rosenthal RN, Perkel C, Singh P, et al. A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict. 1998 Summer;7(3):189–97. Exclusion Code: X6. [PubMed: 9702286]

309.

Rosner S, Leucht S, Lehert P, et al. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008 Jan;22(1):11–23. Exclusion Code: X10. [PubMed: 18187529]

310.

Roussaux JP, Hers D, Ferauge M. Does acamprosate influence alcohol consumption of weaned alcoholics? J Pharm Belg. 1996;51(2):65–8. CN-00173028. Exclusion Code: X1. [PubMed: 8786520]

311.

Roy A. Treating depression among alcoholics. Can J Psychiatry. 1996;41(3):194–5. Exclusion Code: X5. [PubMed: 8722652]

312.

Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry. 1998 Oct 1;44(7):633–7. Exclusion Code: X6. [PubMed: 9787889]

313.

Rubio G, Manzanares J, Lopez-Munoz F, et al. Naltrexone improves outcome of a controlled drinking program. J Subst Abuse Treat. 2002 Dec;23(4):361–6. Exclusion Code: X8. [PubMed: 12495798]

314.

Rubio G, Ponce G, Jimenez-Arriero MA, et al. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry. 2004 Jan;37(1):37–40. Exclusion Code: X5. [PubMed: 14750047]

315.

Rubio G, Ponce G, Rodriguez-Jimenez R, et al. Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol. 2005 May-Jun;40(3):227–33. Exclusion Code: X5. [PubMed: 15797885]

316.

Schaumberg K, Kuerbis A, Morgenstern J, et al. Attributions of Change and Self-Efficacy in a Randomized Controlled Trial of Medication and Psychotherapy for Problem Drinking. Behav Ther. 2013;44(1):88–99. Exclusion Code: X6. [PMC free article: PMC3556396] [PubMed: 23312429]

317.

Schmidt LG, Smolka MN. Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers. Alcohol Alcohol. 2007 May-Jun;42(3):241–6. Exclusion Code: X8. [PubMed: 17526634]

318.

Scott C, Corbin WR, Leeman RF, et al. The influence of initial subjective response and acquired tolerance to alcohol on drinking behavior and problems in a clinical sample. Alcohol. 2011;35:165A. Exclusion Code: X6.

319.

Sellers EM, Higgins GA, Tompkins DM, et al. Serotonin and alcohol drinking. NIDA Res Monogr. 1992;119:141–5. Exclusion Code: X9. [PubMed: 1435969]

320.

Sellers EM, Naranjo CA, Kadlec K. Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy drinkers. J Clin Psychopharmacol. 1987 Dec;7(6):417–20. Exclusion Code: X8. [PubMed: 2963034]

321.

Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994 Aug;18(4):879–85. Exclusion Code: X9. [PubMed: 7978099]

322.

Seneviratne C, Johnson BA. Serotonin transporter genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics. Front Psychiatry. 2012;3 Exclusion Code: X6. [PMC free article: PMC3314249] [PubMed: 22470354]

323.

Shin S, Livchits V, Connery HS, et al. Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia. Addiction. 2013;108(8):1387–96. 2013-25290-007. First Author & Affiliation: Shin, Sonya. Exclusion Code: X5. [PMC free article: PMC3710528] [PubMed: 23490304]

324.

Simon GE, Heiligenstein J, Revicki D. More people with depression continued treatment with fluoxetine than with desipramine or imipramine. Evid Based Med. 2000;5(2):51. Exclusion Code: X3.

325.

Simpson TL, Saxon AJ, Meredith CW, et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res. 2009 Feb;33(2):255–63. Exclusion Code: X9. [PubMed: 18945226]

326.

Sloan TB, Roache JD, Johnson BA. The role of anxiety in predicting drinking behaviour. Alcohol Alcohol. 2003 Jul-Aug;38(4):360–3. Exclusion Code: X9. [PubMed: 12814905]

327.

Smith Erica J, Lui S, Terplan M. Cochrane Database Syst Rev. John Wiley & Sons, Ltd; 2009. Pharmacologic Interventions for Pregnant Women Enrolled in Alcohol Treatment. Exclusion Code: X6. [PMC free article: PMC7208248] [PubMed: 19588428]

328.

Snyder JL, Bowers TG. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse. 2008;34(4):449–61. Exclusion Code: X10. [PubMed: 18584575]

329.

Snyder S, Karacan I, Salis PJ. Disulfiram and nocturnal penile tumescence in the chronic alcoholic. Biol Psychiatry. 1981 Apr;16(4):399–406. Exclusion Code: X6. [PubMed: 7225493]

330.

Snyder S, Karacan I, Salis PJ. Effects of disulfiram on the sleep of chronic alcoholics. Curr Alcohol. 1981;8:159–66. Exclusion Code: X7. [PubMed: 6282542]

331.

Snyder S, Keeler M. Acute effects of disulfiram on anxiety levels of chronic alcoholics. Int Pharmacopsychiatry. 1981;16(1):49–56. Exclusion Code: X7. [PubMed: 7028657]

332.

Soyka M, Sass H. Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism--preliminary data. Alcohol Alcohol Suppl. 1994;2:531–6. Exclusion Code: X6. [PubMed: 8974379]

333.

Specka M, Lieb B, Kuhlmann T, et al. Marked reduction of heavy drinking did not reduce nicotine use over 1 year in a clinical sample of alcohol-dependent patients. Pharmacopsychiatry. 2011;44(3):120–1. Exclusion Code: X6. [PubMed: 21298613]

334.

Spies CD, Dubisz N, Neumann T, et al. Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Crit Care Med. 1996 Mar;24(3):414–22. Exclusion Code: X3. [PubMed: 8625628]

335.

Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2005 Jun;8(2):267–80. Exclusion Code: X10. [PubMed: 15850502]

336.

Staner L, Boeijinga P, Danel T, et al. Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. Alcohol Clin Exp Res. 2006 Sep;30(9):1492–9. Exclusion Code: X6. [PubMed: 16930211]

337.

Stapleton JM, Eckardt MJ, Martin P, et al. Treatment of alcoholic organic brain syndrome with the serotonin reuptake inhibitor fluvoxamine: a preliminary study. Adv Alcohol Subst Abuse. 1988;7(3-4):47–51. Exclusion Code: X6. [PubMed: 2464912]

338.

Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001 Nov-Dec;36(6):544–52. Exclusion Code: X10. [PubMed: 11704620]

339.

Su N, Zhang L, Fei F, et al. The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res. 2011 Sep 30;1415:119–26. Exclusion Code: X9. [PubMed: 21880305]

340.

Suh JJ, Pettinati HM, Kampman KM, et al. Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict. 2008 Nov-Dec;17(6):463–8. Exclusion Code: X6. [PMC free article: PMC2657877] [PubMed: 19034737]

341.

Swearingen CE, Moyer A, Finney JW. Alcoholism treatment outcome studies, 1970-1998: An expanded look at the nature of the research. Addict Behav. 2003;28(3):415–36. Exclusion Code: X6. [PubMed: 12628616]

342.

Swift R. Emerging approaches to managing alcohol dependence. Am J Health Syst Pharm. 2007;64(5 Suppl):S12–S22. Exclusion Code: X2. [PubMed: 17322178]

343.

Swift RM. The pharmacotherapy of alcohol dependence: Clinical and economic aspects. Econ Neurosci. 2001;3(12):62–6. Exclusion Code: X2.

344.

Tauscher-Wisniewski S, Disch D, Plewes J, et al. Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder. Psychol Med. 2007;37(11):1585–93. Exclusion Code: X3. [PubMed: 17640442]

345.

Thevos AK, Brown JM, Malcolm R, et al. Alcohol treatment: measurement of effectiveness by global outcome. Soc Work Health Care. 1996;23(3):57–71. Exclusion Code: X6. [PubMed: 8865515]

346.

Tidey JW, Monti PM, Rohsenow DJ, et al. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res. 2008 Jan;32(1):58–66. Exclusion Code: X9. [PMC free article: PMC2743136] [PubMed: 18028530]

347.

Tollefson GD. Serotonin and alcohol: Interrelationships. Psychopathology. 1989;22(SUPPL. 1):37–48. Exclusion Code: X8. [PubMed: 2567040]

348.

Tolliver BK, Brady KT. Glutamate neurotransmission as a potential therapeutic target in bipolar disorder: An overview of evidence and implications for treatment of co-occurring disorders. Bipolar Disord. 2011;13:100. Exclusion Code: X9.

349.

Tolliver BK, Desantis SM, Brown DG, et al. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2012 Feb;14(1):54–63. Exclusion Code: X9. [PubMed: 22329472]

350.

Tolliver BK, McRae AL, Sonne SC, et al. Safety and tolerability of acamprosate in alcohol-dependent individuals with bipolar disorder: An open-label pilot study. Addict Disord Their Treat. 2009;8(1):33–8. Exclusion Code: X8.

351.

Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict. 2009 May-Jun;18(3):219–25. Exclusion Code: X9. [PubMed: 19340640]

352.

Trevisan LA, Ralevski E, Keegan K, et al. Alcohol detoxification and relapse prevention using valproic acid versus gabapentin in alcohol-dependent patients. Addict Disord Their Treat. 2008;7(3):119–28. Exclusion Code: X9.

353.

Ulmer A, Müller M, Frietsch B. Dihydrocodeine/agonists for alcohol dependents. Front Psychiatry. 2012;3 Exclusion Code: X8. [PMC free article: PMC3311265] [PubMed: 22470353]

354.

Ulrichsen J, Nielsen MK, Ulrichsen M. Disulfiram in severe alcoholisman open controlled study. Nord J Psychiatry. 2010;64(6):356–62. Exclusion Code: X5. [PubMed: 20297945]

355.

van den Brink W, Aubin HJ, Bladstrom A, et al. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013 Sep-Oct;48(5):570–8. Exclusion Code: X8. [PMC free article: PMC3746807] [PubMed: 23873853]

356.

Vaughan MD, Hook JN, Wagley JN, et al. Changes in affect and drinking outcomes in a pharmacobehavioral trial for alcohol dependence. Addict Disord Their Treat. 2012;11(1):14–25. Exclusion Code: X6. [PMC free article: PMC3285393] [PubMed: 22368517]

357.

Vaz de Lima Fabiana B, Andriolo Régis B, da Silveira Dartiu X. Dopaminergic antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(4):CD008460. Exclusion Code: X8.

358.

Verheul R, Lehert P, Geerlings PJ, et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl). 2005 Mar;178(2-3):167–73. Exclusion Code: X8. [PubMed: 15322728]

359.

Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol ‘high’ in alcoholics. Am J Psychiatry. 1995;152(4):613–5. Exclusion Code: X8. [PubMed: 7694913]

360.

Voronin K, Randall P, Myrick H, et al. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Alcohol Clin Exp Res. 2008 Nov;32(11):1954–61. Exclusion Code: X7. [PMC free article: PMC2588475] [PubMed: 18782344]

361.

Weinrieb RM, O'Brien CP. Naltrexone in the treatment of alcoholism. Annu Rev Med. 1997;48:477–87. Exclusion Code: X8. [PubMed: 9046978]

362.

Weinrieb RM, Van Horn DH, McLellan AT, et al. Alcoholism treatment after liver transplantation: lessons learned from a clinical trial that failed. Psychosomatics. 2001 Mar-Apr;42(2):110–6. Exclusion Code: X6. [PubMed: 11239123]

363.

Wilens TE, Adler LA, Tanaka Y, et al. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Curr Med Res Opin. 2011 Dec;27(12):2309–20. Exclusion Code: X5. [PMC free article: PMC3772672] [PubMed: 22029549]

364.

Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol abuse; Proceedings of the 69th Annual Scientific Meeting of the College on Problems of Drug Dependence; 2007 June 16-21; Quebec City, Canada. 2007. Exclusion Code: X8.

365.

Witkiewitz K. Predictors of heavy drinking during and following treatment. Psychol Addict Behav. 2011;25(3):426–38. Exclusion Code: X6. [PMC free article: PMC3236107] [PubMed: 21480681]

366.

Witte J, Bentley K, Evins AE, et al. A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. J Clin Psychopharmacol. 2012;32(6):787–96. Exclusion Code: X4. [PMC free article: PMC3794470] [PubMed: 23131884]

367.

Workeneh B, Balakumaran A, Bichet DG, et al. The dilemma of diagnosing the cause of hypernatraemia: Drinking habits vs diabetes insidipus. Nephrol Dial Transplant. 2004;19(12):3165–7. Exclusion Code: X8. [PubMed: 15575005]

368.

Yen MH, Ko HC, Tang FI, et al. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol. 2006 Feb;38(2):117–20. Exclusion Code: X8. [PubMed: 16839858]

369.

Zarkin GA, Bray JW, Aldridge A, et al. The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study. Med Care. 2010 May;48(5):396–401. Exclusion Code: X6. [PMC free article: PMC3130073] [PubMed: 20393362]